MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 2 of 3)

MMC、VICC

• 批准号: 8541774
• 负责人: HAROLD L MOSES
• 金额: $ 80.03万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-23 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8541774
• 关键词: Address; Advisory Committees; African American; Age; Award; Biology; Biometry; Breast; Cancer Burden; Cancer Center; Cancer Research Infrastructure; Chemistry; Clinical; Clinical Trials; Collaborations; Colorectal; Commit; Communities; Community Healthcare; Community Outreach; Comprehensive Cancer Center; Consensus; Core Facility; Development; Diagnosis; Discipline; Discipline of Nursing; Effectiveness; Environment; Epidemiology; Faculty; Funding; Goals; Histopathology; Human Resources; Incidence; Institution; Joints; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of lung; Measurable; Minority; Minority-Serving Institution; Mission; Monitor; Nanotechnology; National Cancer Institute; Outcome; Participant; Phase; Pilot Projects; Population; Positioning Attribute; Prevention strategy; Primary Prevention; Prostate; Recruitment Activity; Relative (related person); Research; Research Infrastructure; Research Personnel; Research Training; Resources; Science; Scientist; Services; Strategic Planning; Targeted Research; Tennessee; Training; Training Programs; Translational Research; Triad Acrylic Resin; Underrepresented Minority; United States; Universities; Work; anticancer research; base; cancer education; cancer health disparity; cancer therapy; cancer type; career development; design; graduate student; health disparity; improved; medical schools; member; mortality; multidisciplinary; outreach; population based; programs; research and development; success; undergraduate student

Strong ties have developed between cancer researchers at Meharry Medical College (MMC), Tennessee State University (TSU) and Vanderbilt-lngram Cancer Center (VICC) resulting in this formal Cancer Partnership. Our Partnership is dedicated to enhancing the strengths and eliminating the weaknesses of our three institutions as we move toward our shared goal of eliminating cancer disparities in the US. The U54 award is the bedrock of this collaboration and has moved our collaborative research more forcefully toward a relationship that is based on reciprocity and stronger mutual benefit. The overall objectives of this competing renewal application are: (1) to increase and stabilize the competitive cancer research capability of MMC and TSU; (2) to create stable, long-term collaborative relationships between MMC, TSU and the VICC in cancer research, research training, career development and cancer outreach; and (3) to improve the effectiveness of VICC research, training, career development, cancer education and cancer outreach activities specifically designed to benefit minority populations in the region served by VICC. Funds provided by this U54 will solidify our collaboration. During this phase of our Cancer Partnership, we continue to concentrate on amassing sufficient infrastructure for cancer research that will strengthen reciprocity between MMC, TSU and VICC. In addition to funding two full projects and two pilot studies involving collaborators from all three institutions, funds will be used to recruit investigators to TSU and VICC and to strengthen infrastructure in basic, epidemiologic and clinical cancer research through the support of core facilities providing expertise in biostatistics, clinical trial accruals, histopathology and cancer outreach. All activities involve coordinated, well-planned interactions between MMC, TSU and VICC and will be monitored by an Internal Advisory Committee composed of members from each institution and a Program Steering Committee composed of external, nationally-recognized cancer investigators and representation from the National Cancer Institute. A sustained and comprehensive Cancer Partnership is of immense benefit to the three participating institutions as well as the mid-South region of the US. The institution's complementary strengths will help the Cancer Partnership establish effective cancer research and increase training opportunities at two minority-serving institutions enhance community- and population-based science research targeting minority cancer-related disparities and increase training of minority scientists at an NCI-funded Comprehensive Cancer Center.

梅哈里医学院（MMC）、田纳西州立大学（大津）和范德比尔特-英格拉姆癌症中心（VICC）的癌症研究人员之间建立了牢固的联系，从而形成了这一正式的癌症伙伴关系。我们的合作伙伴关系致力于加强我们三个机构的优势，消除我们的弱点，因为我们朝着消除美国癌症差距的共同目标前进。U 54奖是这种合作的基石，并使我们的合作研究更有力地走向基于互惠和更强互利的关系。本次竞争性续约申请的总体目标是：（1）提高和稳定MMC和大津在癌症研究方面的竞争力;（2）在MMC、大津和VICC之间建立稳定、长期的合作关系，包括癌症研究、研究培训、职业发展和癌症外展;以及（3）提高VICC研究、培训、职业发展、癌症教育和癌症外展活动的有效性，这些活动是专门为VICC服务区域内的少数民族人口而设计的。U 54提供的资金将巩固我们的合作。在我们的癌症伙伴关系的这一阶段，我们继续集中精力为癌症研究积累足够的基础设施，这将加强MMC、大津和VICC之间的互惠。除了资助两个完整的项目和两个试点研究，涉及所有三个机构的合作者，资金将被用来招募调查员到大津和VICC和加强基础设施，流行病学和临床癌症研究通过支持核心设施提供专业知识，在生物统计，临床试验累积，组织病理学和癌症外展。所有活动都涉及MMC、大津和VICC之间协调、精心策划的互动，并将由内部咨询委员会和项目指导委员会进行监测，内部咨询委员会由各机构的成员组成，项目指导委员会由外部、国家认可的癌症研究者和国家癌症研究所的代表组成。一个持续和全面的癌症伙伴关系对三个参与机构以及美国中南部地区都有巨大的好处。该机构的互补优势将帮助癌症伙伴关系建立有效的癌症研究，并增加两个少数民族服务机构的培训机会，加强针对少数民族癌症相关差异的社区和人口科学研究，并增加对NCI资助的综合癌症中心少数民族科学家的培训。